secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metsera, Inc. (—)
CIK:        0002040807
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001193125-25-100859
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Metsera appoints Jon Stonehouse to Board and Matt Lang as Chief Legal Officer
-----------------------------------------------------------------------------

- Jon P. Stonehouse appointed to Board (Class III) and Audit Committee effective April 28, 2025.
- Matthew Lang appointed Chief Legal Officer and Secretary; previously CBO/CLO at Lyell Immunopharma.
- Stonehouse receives option award vesting in 36 equal monthly installments under director comp plan.
- Stonehouse is CEO of BioCryst Pharmaceuticals; brings M&A and pharma leadership experience.
- Lang's background includes executive roles at Myovant Sciences and Gilead Sciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2040807/000119312525100859/0001193125-25-100859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2040807/000119312525100859/d116647d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-100859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer